Diligence memo · auto-generated · as of July 2, 2026
Syncromune, Inc.
Syncromune, Inc. looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
Syncromune, Inc. operates in Biotechnology, based in FORT LAUDERDALE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Syncromune, Inc. has raised $65M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $112M on 2024-12-03.
Most recent recorded round closed around 2024-12-03.
Valuation (modeled)modeled
Provath models Syncromune, Inc. at approximately $386M (range $157M–$553M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.78× the median modeled value of Series C Biotechnology companies in 2022–2024 (111 peers) — value vs value, same stage and era. Within the normal band (78% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 10 months.
Last raise 19 mo ago; this sector typically re-raises about every 14 months.
Slightly overdue versus sector cadence.
The last round was 2.2× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 86% of Biotechnology peers (4293 compared).
Modeled value ranks above 80% of those peers.
Closest niche peers: Dianthus Therapeutics, Inc., Satellite Biosciences, Inc., Deepcell, Inc., Ventus Therapeutics U.S., Inc., Morphic Holding, Inc..
Peoplefiled
11 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.